Do novel risk factors differ between men and women aged 18 to 39 years with a high risk of coronary heart disease?

Metabolism: Clinical and Experimental

Volumn 56, Issue 2, 2007, Pages 260-266

  Tonstad, Serena ^a   Thorsrud, Hege ^a   Torjesen, Peter A ^b   Seljeflot, Ingebjørg ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ARGININE; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; N(G),N(G) DIMETHYLARGININE; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ARTICLE; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE MARKER; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FAMILY HISTORY; FEMALE; HIGH RISK POPULATION; HORMONAL CONTRACEPTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OXIDATION; PREMENOPAUSE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SUGAR INTAKE; THROMBOSIS;

EID: 33846109178     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.10.006     Document Type: Article

References (40)

1. Snowden C.B., McNamara P.M., Garrison R.J., Feinleib M., Kannel W.B., and Epstein F.H. Predicting coronary heart disease in siblings-a multivariate assessment. Am J Epidemiol 115 (1982) 217-222
2. Clarkson P., Celermajer D.S., Powe A.J., Donald A.E., Henry R.M., and Deanfield J.E. Endothelium-dependent dilatation is impaired in young adults with a family history of premature coronary disease. Circulation 96 (1997) 3378-3383
3. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 358 (2001) 2096-2097
4. Ridker P., Vaughan D., Stampfer M., Manson J., and Hennekens C. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341 (1993) 1165-1168
5. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., and Allen J. Plasma levels of soluble intercellular adhesion molecule-1 and risks of future myocardial infarction in apparently healthy men. Lancet 351 (1998) 88-92
6. Salomaa V., Matei C., Aleksic N., et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 353 (1999) 1729-1734
7. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma levels of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
8. Malik I., Danesh J., Whincup P., et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358 (2001) 971-975
9. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108 (2003) 2317-2322
10. Pai J.K., Pischon T., Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351 (2004) 2599-2610
11. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 (2004) 1387-1397
12. Pankow J.S., Folsom A.R., Province M.A., et al., on behalf of the Atherosclerosis Risk in Communities investigators and Family Heart Study Research Group. Family history of coronary heart disease and hemostatic variables in middle-aged adults. Thromb Haemost 77 (1997) 87-93
13. Mills J.D., Mansfield M.W., and Grant P.J. Tissue plasminogen activator, fibrin D-dimer, and insulin resistance in the relatives of patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 22 (2002) 704-709
14. Rohde L.E.P., Hennekens C.H., and Ridker P.M. Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arterioscler Thromb Vasc Biol 19 (1999) 1595-1599
15. Margaglione M., Cappucci G., Colaizzo D., Vecchione G., Grandone E., and DiMinno G. C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives. Arterioscler Thromb Vasc Biol 20 (2000) 198-1203
16. Pichon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
17. Wallace A.M., McMahon A.D., Packard C.J., et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104 (2001) 3052-3056
18. Gaeta G., de Michele M., Cuomo S., et al. Arterial abnormalities in the offspring of patients with premature myocardial infarction. N Engl J Med 343 (2000) 840-846
19. Nava-Nacher E.L., Colangelo L., Beam C., and Grennland P. Risk factors for coronary heart disease in men 18 to 39 years of age. Ann Intern Med 134 (2001) 433-439
20. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 24 (2003) 1601-1610
21. Tonstad S., and Westheim A. Implementation of guidelines to screen relatives of patients with premature CHD. Am J Cardiol 90 (2002) 1211-1214
22. Tonstad S., Sundfør T., and Seljeflot I. Effect of lifestyle changes on atherogenic lipids and endothelial cell adhesion molecules in young adults with familial premature coronary heart disease. Am J Cardiol 95 (2005) 1187-1191
23. Andersen L.F., Solvoll K., Johansson L.R.K., Salminen I., Aro A., and Drevon C.A. Evaluation of a food frequency questionnaire with weighted records, fatty acids and alpha-tocopherol in adipose tissue and serum. Am J Epidemiol 150 (1999) 75-87
24. Anderssen S.A., Damm F.R., Bjerkan K., Løvø A., and Hustvedt B.E. Registration of physical activity and energy expenditure: validity control of a questionnaire. Med Sci Sport Exerc Suppl 32 (2000) 81
25. Hostmark A.T., and Lystad E. Growth inhibition of human hepatoma cells (HepG2) by polyunsaturated fatty acids. Protection by albumin and vitamin E. Acta Physiol Scand 144 (1992) 83-88
26. Eid H.M., Eritsland J., Larsen J., Arnesen H., and Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 166 (2003) 279-284
27. Hinderliter A.L., and Caughey M. Assessing endothelial function as a risk factor for cardiovascular disease. Curr Atheroscler Rep 5 (2003) 506-513
28. Schumacher A., Seljeflot I., Sommervoll L., Christensen B., Otterstad J.E., and Arnesen H. Increased levels of markers of vascular inflammation in patients with coronary heart disease. Scand J Clin Lab Invest 62 (2002) 59-68
29. Ponthieux A., Herbeth B., Droesch S., Haddy N., Lambert D., and Visvikis S. Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study. Atherosclerosis 172 (2004) 299-308
30. Eliasson M., Evrin P.-E., Lundblad D., Asplund K., and Rånby M. Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen. Fibrinolysis 7 (1993) 316-323
31. von Eynatten M., Schneider J.G., Humpert P.M., et al. Decreased plasma lipoprotein lipase in hypoadiponectinemia. Diabetes Care 27 (2004) 2925-2929
32. Jovinge S., Hamsten A., Tornvall P., et al. Evidence for a role of tumor necrosis factorα in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 47 (1998) 113-118
33. Post M.S., Verhoeven M.O., Van der Mooren M.J., et al. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab 88 (2003) 4221-4226
34. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
35. Bermudez E.A., Rifai N., Buring J., Manson J.E., and Ridker P.M. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 22 (2002) 1668-1673
36. Herrington D.M., and Klein K.P. Randomized clinical trials of hormone replacement therapy for treatment or prevention of cardiovascular disease: a review of the findings. Atherosclerosis 166 (2003) 203-212
37. Rosenbaum M., Nicolson M., Hirsch J., et al. Effects of gender, body composition, and menopause on plasma levels of leptin. J Clin Endocrinol Metab 81 (1996) 3424-3427
38. Eid H.M.A., Arnesen H., Hjerkinn E.M., Lyberg T., and Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism 53 (2004) 1574-1579
39. Porreca E., Di Febbo C., Moretta V., et al. Circulating leptin is associated with oxidized LDL in postmenopausal women. Atherosclerosis 175 (2004) 139-143
40. Reseland J.E., Mundal H.H., Hollung K., et al. Cigarette smoking may reduce plasma leptin concentration via catecholamines. Prostaglandins Leukot Essent Fat Acids 73 (2005) 43-49